Bromocriptine and Insulin Sensitivity (the BIS study)

Completed

• Conditions: Insulin Sensitivity; Sensitivity for insulin; 10018424

• Registration Number: NL-OMON42270
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 16

Inclusion Criteria

- Male
- Caucasian origin
- Subjects should be able and willing to give informed consent
- 18-35 years old
- BMI range of 19-23 kg/m2 or BMI> 27 kg/2

Exclusion Criteria

- Renal failure (creatinine>135mmol/l)
- Liver failure (AST/ALT > 3 times higher than the normal upper value)
- Daily use of prescription medication and/or drugs
- Known hypersensitivity to bromocriptine.
- Uncontrolled hypertension
- Known history of coronary artery disease or valvulopathy
- History of severe psychiatric disorders.
- Prolactin-releasing pituitary tumor (prolactinoma).

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Difference in insulin sensitivity when bromocriptine is used in the morning or<br /><br>in the evening in lean and obese males.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Difference in effect of bromocriptine treatment on insulin sensitivity<br /><br>between lean and obese males.<br /><br>- Difference in energy expenditure due to bromocriptine usage at different time<br /><br>points in lean and obese males. </p><br>